Cargando…

Multiparametric (18)F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

SIMPLE SUMMARY: In breast cancer, the leading cancer type and the main cause of cancer death in women, achieving pathological complete response after neoadjuvant chemotherapy has been shown to be associated with prolonged overall survival. Hence, the correct assessment and the potential prediction o...

Descripción completa

Detalles Bibliográficos
Autores principales: Umutlu, Lale, Kirchner, Julian, Bruckmann, Nils-Martin, Morawitz, Janna, Antoch, Gerald, Ting, Saskia, Bittner, Ann-Kathrin, Hoffmann, Oliver, Häberle, Lena, Ruckhäberle, Eugen, Catalano, Onofrio Antonio, Chodyla, Michal, Grueneisen, Johannes, Quick, Harald H., Fendler, Wolfgang P., Rischpler, Christoph, Herrmann, Ken, Gibbs, Peter, Pinker, Katja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996836/
https://www.ncbi.nlm.nih.gov/pubmed/35406499
http://dx.doi.org/10.3390/cancers14071727
_version_ 1784684563652411392
author Umutlu, Lale
Kirchner, Julian
Bruckmann, Nils-Martin
Morawitz, Janna
Antoch, Gerald
Ting, Saskia
Bittner, Ann-Kathrin
Hoffmann, Oliver
Häberle, Lena
Ruckhäberle, Eugen
Catalano, Onofrio Antonio
Chodyla, Michal
Grueneisen, Johannes
Quick, Harald H.
Fendler, Wolfgang P.
Rischpler, Christoph
Herrmann, Ken
Gibbs, Peter
Pinker, Katja
author_facet Umutlu, Lale
Kirchner, Julian
Bruckmann, Nils-Martin
Morawitz, Janna
Antoch, Gerald
Ting, Saskia
Bittner, Ann-Kathrin
Hoffmann, Oliver
Häberle, Lena
Ruckhäberle, Eugen
Catalano, Onofrio Antonio
Chodyla, Michal
Grueneisen, Johannes
Quick, Harald H.
Fendler, Wolfgang P.
Rischpler, Christoph
Herrmann, Ken
Gibbs, Peter
Pinker, Katja
author_sort Umutlu, Lale
collection PubMed
description SIMPLE SUMMARY: In breast cancer, the leading cancer type and the main cause of cancer death in women, achieving pathological complete response after neoadjuvant chemotherapy has been shown to be associated with prolonged overall survival. Hence, the correct assessment and the potential prediction of therapy response have recently become the focus of research. In this study, we predicted pathological complete response prior to neoadjuvant system therapy using (18)F-FDG PET/MRI radiomics analysis of the breast. Hence, simultaneous (18)F-FDG PET/MRI may enable a more individualized and targeted approach to treatment as well as pretherapeutic patient stratification. ABSTRACT: Background: The aim of this study was to assess whether multiparametric (18)F-FDG PET/MRI-based radiomics analysis is able to predict pathological complete response in breast cancer patients and hence potentially enhance pretherapeutic patient stratification. Methods: A total of 73 female patients (mean age 49 years; range 27–77 years) with newly diagnosed, therapy-naive breast cancer underwent simultaneous (18)F-FDG PET/MRI and were included in this retrospective study. All PET/MRI datasets were imported to dedicated software (ITK-SNAP v. 3.6.0) for lesion annotation using a semi-automated method. Pretreatment biopsy specimens were used to determine tumor histology, tumor and nuclear grades, and immunohistochemical status. Histopathological results from surgical tumor specimens were used as the reference standard to distinguish between complete pathological response (pCR) and noncomplete pathological response. An elastic net was employed to select the most important radiomic features prior to model development. Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were calculated for each model. Results: The best results in terms of AUCs and NPV for predicting complete pathological response in the entire cohort were obtained by the combination of all MR sequences and PET (0.8 and 79.5%, respectively), and no significant differences from the other models were observed. In further subgroup analyses, combining all MR and PET data, the best AUC (0.94) for predicting complete pathologic response was obtained in the HR+/HER2− group. No difference between results with/without the inclusion of PET characteristics was observed in the TN/HER2+ group, each leading to an AUC of 0.92 for all MR and all MR + PET datasets. Conclusion: (18)F-FDG PET/MRI enables comprehensive high-quality radiomics analysis for the prediction of pCR in breast cancer patients, especially in those with HR+/HER2− receptor status.
format Online
Article
Text
id pubmed-8996836
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89968362022-04-12 Multiparametric (18)F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Umutlu, Lale Kirchner, Julian Bruckmann, Nils-Martin Morawitz, Janna Antoch, Gerald Ting, Saskia Bittner, Ann-Kathrin Hoffmann, Oliver Häberle, Lena Ruckhäberle, Eugen Catalano, Onofrio Antonio Chodyla, Michal Grueneisen, Johannes Quick, Harald H. Fendler, Wolfgang P. Rischpler, Christoph Herrmann, Ken Gibbs, Peter Pinker, Katja Cancers (Basel) Article SIMPLE SUMMARY: In breast cancer, the leading cancer type and the main cause of cancer death in women, achieving pathological complete response after neoadjuvant chemotherapy has been shown to be associated with prolonged overall survival. Hence, the correct assessment and the potential prediction of therapy response have recently become the focus of research. In this study, we predicted pathological complete response prior to neoadjuvant system therapy using (18)F-FDG PET/MRI radiomics analysis of the breast. Hence, simultaneous (18)F-FDG PET/MRI may enable a more individualized and targeted approach to treatment as well as pretherapeutic patient stratification. ABSTRACT: Background: The aim of this study was to assess whether multiparametric (18)F-FDG PET/MRI-based radiomics analysis is able to predict pathological complete response in breast cancer patients and hence potentially enhance pretherapeutic patient stratification. Methods: A total of 73 female patients (mean age 49 years; range 27–77 years) with newly diagnosed, therapy-naive breast cancer underwent simultaneous (18)F-FDG PET/MRI and were included in this retrospective study. All PET/MRI datasets were imported to dedicated software (ITK-SNAP v. 3.6.0) for lesion annotation using a semi-automated method. Pretreatment biopsy specimens were used to determine tumor histology, tumor and nuclear grades, and immunohistochemical status. Histopathological results from surgical tumor specimens were used as the reference standard to distinguish between complete pathological response (pCR) and noncomplete pathological response. An elastic net was employed to select the most important radiomic features prior to model development. Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were calculated for each model. Results: The best results in terms of AUCs and NPV for predicting complete pathological response in the entire cohort were obtained by the combination of all MR sequences and PET (0.8 and 79.5%, respectively), and no significant differences from the other models were observed. In further subgroup analyses, combining all MR and PET data, the best AUC (0.94) for predicting complete pathologic response was obtained in the HR+/HER2− group. No difference between results with/without the inclusion of PET characteristics was observed in the TN/HER2+ group, each leading to an AUC of 0.92 for all MR and all MR + PET datasets. Conclusion: (18)F-FDG PET/MRI enables comprehensive high-quality radiomics analysis for the prediction of pCR in breast cancer patients, especially in those with HR+/HER2− receptor status. MDPI 2022-03-29 /pmc/articles/PMC8996836/ /pubmed/35406499 http://dx.doi.org/10.3390/cancers14071727 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Umutlu, Lale
Kirchner, Julian
Bruckmann, Nils-Martin
Morawitz, Janna
Antoch, Gerald
Ting, Saskia
Bittner, Ann-Kathrin
Hoffmann, Oliver
Häberle, Lena
Ruckhäberle, Eugen
Catalano, Onofrio Antonio
Chodyla, Michal
Grueneisen, Johannes
Quick, Harald H.
Fendler, Wolfgang P.
Rischpler, Christoph
Herrmann, Ken
Gibbs, Peter
Pinker, Katja
Multiparametric (18)F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
title Multiparametric (18)F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
title_full Multiparametric (18)F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
title_fullStr Multiparametric (18)F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
title_full_unstemmed Multiparametric (18)F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
title_short Multiparametric (18)F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
title_sort multiparametric (18)f-fdg pet/mri-based radiomics for prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996836/
https://www.ncbi.nlm.nih.gov/pubmed/35406499
http://dx.doi.org/10.3390/cancers14071727
work_keys_str_mv AT umutlulale multiparametric18ffdgpetmribasedradiomicsforpredictionofpathologicalcompleteresponsetoneoadjuvantchemotherapyinbreastcancer
AT kirchnerjulian multiparametric18ffdgpetmribasedradiomicsforpredictionofpathologicalcompleteresponsetoneoadjuvantchemotherapyinbreastcancer
AT bruckmannnilsmartin multiparametric18ffdgpetmribasedradiomicsforpredictionofpathologicalcompleteresponsetoneoadjuvantchemotherapyinbreastcancer
AT morawitzjanna multiparametric18ffdgpetmribasedradiomicsforpredictionofpathologicalcompleteresponsetoneoadjuvantchemotherapyinbreastcancer
AT antochgerald multiparametric18ffdgpetmribasedradiomicsforpredictionofpathologicalcompleteresponsetoneoadjuvantchemotherapyinbreastcancer
AT tingsaskia multiparametric18ffdgpetmribasedradiomicsforpredictionofpathologicalcompleteresponsetoneoadjuvantchemotherapyinbreastcancer
AT bittnerannkathrin multiparametric18ffdgpetmribasedradiomicsforpredictionofpathologicalcompleteresponsetoneoadjuvantchemotherapyinbreastcancer
AT hoffmannoliver multiparametric18ffdgpetmribasedradiomicsforpredictionofpathologicalcompleteresponsetoneoadjuvantchemotherapyinbreastcancer
AT haberlelena multiparametric18ffdgpetmribasedradiomicsforpredictionofpathologicalcompleteresponsetoneoadjuvantchemotherapyinbreastcancer
AT ruckhaberleeugen multiparametric18ffdgpetmribasedradiomicsforpredictionofpathologicalcompleteresponsetoneoadjuvantchemotherapyinbreastcancer
AT catalanoonofrioantonio multiparametric18ffdgpetmribasedradiomicsforpredictionofpathologicalcompleteresponsetoneoadjuvantchemotherapyinbreastcancer
AT chodylamichal multiparametric18ffdgpetmribasedradiomicsforpredictionofpathologicalcompleteresponsetoneoadjuvantchemotherapyinbreastcancer
AT grueneisenjohannes multiparametric18ffdgpetmribasedradiomicsforpredictionofpathologicalcompleteresponsetoneoadjuvantchemotherapyinbreastcancer
AT quickharaldh multiparametric18ffdgpetmribasedradiomicsforpredictionofpathologicalcompleteresponsetoneoadjuvantchemotherapyinbreastcancer
AT fendlerwolfgangp multiparametric18ffdgpetmribasedradiomicsforpredictionofpathologicalcompleteresponsetoneoadjuvantchemotherapyinbreastcancer
AT rischplerchristoph multiparametric18ffdgpetmribasedradiomicsforpredictionofpathologicalcompleteresponsetoneoadjuvantchemotherapyinbreastcancer
AT herrmannken multiparametric18ffdgpetmribasedradiomicsforpredictionofpathologicalcompleteresponsetoneoadjuvantchemotherapyinbreastcancer
AT gibbspeter multiparametric18ffdgpetmribasedradiomicsforpredictionofpathologicalcompleteresponsetoneoadjuvantchemotherapyinbreastcancer
AT pinkerkatja multiparametric18ffdgpetmribasedradiomicsforpredictionofpathologicalcompleteresponsetoneoadjuvantchemotherapyinbreastcancer